Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier to treat severe COVID-19 in India.
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.
"Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high quality clinical site may improve our enrollment of patients who go on to require ICU care for severe infection," commented Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical.
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout India. The initial site for the ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for enrollment, with one patient treated to date.